Clinical Trial Update: Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety and tolerability of CD19x22 CAR T cells in adolescents and adults with relapsed/refractory B-cell non-Hodgkin lymphoma, including…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Central Nervous System Lymphoma
• Mantle Cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• CD19x22 CAR T cells

Snippet

Sponsor: University of Colorado, Denver | Conditions: Non-Hodgkin Lymphoma, B-cell Non-Hodgkin Lymphoma (B-NHL) | Phase 1 | Status: RECRUITING